APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases

Annals of Surgery

Volumn 272, Issue 6, 2020, Pages 1080-1085

  Yamashita, Suguru ^a   Chun, Yun Shin ^a   Kopetz, Scott E ^a   Maru, Dipen ^a   Conrad, Claudius ^a   Aloia, Thomas A ^a   Vauthey, Jean Nicolas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

APC; colorectal liver metastases; mutational; PIK3CA

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; APC PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 85017142145     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002245     Document Type: Article

References (25)

1. Kopetz S, Chang GJ, Overman MJ,. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
2. Blazer DG 3rd, Kishi Y, Maru DM,. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008; 26: 5344-5351.
3. Rubbia-Brandt L, Giostra E, Brezault C,. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
4. Vauthey JN, Zimmitti G, Kopetz SE,. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258: 619-626.
5. Brudvik KW, Kopetz SE, Li L,. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 2015; 102: 1175-1183.
6. Frankel TL, Vakiani E, Nathan H,. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer 2016; 123: 568-575.
7. Schirripa M, Bergamo F, Cremolini C,. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 2015; 112: 1921-1928.
8. Deming DA, Leystra AA, Nettekoven L,. PIK3CA and APC mutations are synergistic in the development of intestinal cancers. Oncogene 2014; 33: 2245-2254.
9. Hare LM, Phesse TJ, Waring PM,. Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochem J 2014; 458: 251-258.
10. Samuels Y, Wang Z, Bardelli A,. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
11. De Roock W, Claes B, Bernasconi D,. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11: 753-762.
12. Singh RR, Patel KP, Routbort MJ,. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn 2013; 15: 607-622.
13. Fong Y, Fortner J, Sun RL,. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.
14. Douillard JY, Oliner KS, Siena S,. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034.
15. Siena S, Sartore-Bianchi A, Di Nicolantonio F,. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324.
16. Linardou H, Dahabreh IJ, Kanaloupiti D,. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
17. Mise Y, Zimmitti G, Shindoh J,. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 2015; 22: 834-842.
18. Denbo JW, Yamashita S, Passot G,. RAS mutation is associated with decreased survival in patients undergoing repeat hepatectomy for colorectal liver metastases. J Gastrointest Surg 2017; 21: 68-77.
19. Passot G, Chun YS, Kopetz SE,. Predictors of safety and efficacy of 2-stage hepatectomy for bilateral colorectal liver metastases. J Am Coll Surg 2016; 223: 99-108.
20. Heinemann V, von Weikersthal LF, Decker T,. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075.
21. Lipsyc M, Yaeger R,. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol 2015; 6: 645-649.
22. Karapetis CS, Jonker D, Daneshmand M,. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer: results from NCIC CTG/AGITG CO.17. Clin Cancer Res 2014; 20: 744-753.
23. Knijn N, Mekenkamp LJ, Klomp M,. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-1026.
24. Kim R, Schell MJ, Teer JK,. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One 2015; 10: e0126670.
25. Baas JM, Krens LL, Guchelaar HJ,. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist 2011; 16: 1239-1249.